Comparative study of the effects of PACAP in young, aging, and castrated males in a rat model of Parkinson's disease

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

We have previously shown that PACAP ameliorates the neurological symptoms and reduces the dopaminergic cell loss in young male rats, in a 6-hydroxydopamine (6-OHDA)-induced lesion of the substantia nigra, a model of Parkinson's disease. In the present study, we compared the effects of PACAP in young, aging, and castrated males. Our results show that PACAP significantly reduced the dopaminergic cell loss in young and aging males. In castrated males, 6-OHDA did not induce such a severe cell loss, and it was not altered by PACAP. However, PACAP effectively ameliorated behavioral symptoms in all groups, with a degree of recovery depending on age and endocrine status.

Original languageEnglish
Pages (from-to)518-524
Number of pages7
JournalAnnals of the New York Academy of Sciences
Volume1070
DOIs
Publication statusPublished - Jul 2006

Fingerprint

Pituitary Adenylate Cyclase-Activating Polypeptide
Parkinson Disease
Rats
Aging of materials
Oxidopamine
Behavioral Symptoms
Substantia Nigra
Comparative Study
Parkinson's Disease
Rat
Cells
Recovery

Keywords

  • Age
  • Gender
  • Neuroprotection
  • PACAP
  • Parkinson

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

@article{f00ddc2c4be144de983cdb257596cf56,
title = "Comparative study of the effects of PACAP in young, aging, and castrated males in a rat model of Parkinson's disease",
abstract = "We have previously shown that PACAP ameliorates the neurological symptoms and reduces the dopaminergic cell loss in young male rats, in a 6-hydroxydopamine (6-OHDA)-induced lesion of the substantia nigra, a model of Parkinson's disease. In the present study, we compared the effects of PACAP in young, aging, and castrated males. Our results show that PACAP significantly reduced the dopaminergic cell loss in young and aging males. In castrated males, 6-OHDA did not induce such a severe cell loss, and it was not altered by PACAP. However, PACAP effectively ameliorated behavioral symptoms in all groups, with a degree of recovery depending on age and endocrine status.",
keywords = "Age, Gender, Neuroprotection, PACAP, Parkinson",
author = "D. Reglodi and A. Tam{\'a}s and I. Lengv{\'a}ri and G. T{\'o}th and L. Szalontay and A. Lubics",
year = "2006",
month = "7",
doi = "10.1196/annals.1317.072",
language = "English",
volume = "1070",
pages = "518--524",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Comparative study of the effects of PACAP in young, aging, and castrated males in a rat model of Parkinson's disease

AU - Reglodi, D.

AU - Tamás, A.

AU - Lengvári, I.

AU - Tóth, G.

AU - Szalontay, L.

AU - Lubics, A.

PY - 2006/7

Y1 - 2006/7

N2 - We have previously shown that PACAP ameliorates the neurological symptoms and reduces the dopaminergic cell loss in young male rats, in a 6-hydroxydopamine (6-OHDA)-induced lesion of the substantia nigra, a model of Parkinson's disease. In the present study, we compared the effects of PACAP in young, aging, and castrated males. Our results show that PACAP significantly reduced the dopaminergic cell loss in young and aging males. In castrated males, 6-OHDA did not induce such a severe cell loss, and it was not altered by PACAP. However, PACAP effectively ameliorated behavioral symptoms in all groups, with a degree of recovery depending on age and endocrine status.

AB - We have previously shown that PACAP ameliorates the neurological symptoms and reduces the dopaminergic cell loss in young male rats, in a 6-hydroxydopamine (6-OHDA)-induced lesion of the substantia nigra, a model of Parkinson's disease. In the present study, we compared the effects of PACAP in young, aging, and castrated males. Our results show that PACAP significantly reduced the dopaminergic cell loss in young and aging males. In castrated males, 6-OHDA did not induce such a severe cell loss, and it was not altered by PACAP. However, PACAP effectively ameliorated behavioral symptoms in all groups, with a degree of recovery depending on age and endocrine status.

KW - Age

KW - Gender

KW - Neuroprotection

KW - PACAP

KW - Parkinson

UR - http://www.scopus.com/inward/record.url?scp=33746456340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746456340&partnerID=8YFLogxK

U2 - 10.1196/annals.1317.072

DO - 10.1196/annals.1317.072

M3 - Article

C2 - 16888218

AN - SCOPUS:33746456340

VL - 1070

SP - 518

EP - 524

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -